• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Dec. 29, 2015

View Archived Issues

SUPPRESS depresses; Street dings Chimerix to end year with bluesy 'doozy' CMV phase III

CEO Michelle Berrey said Chimerix Inc.'s solid financial position of $378 million in cash at the end of the third quarter will let the firm "make the best strategic decisions around the brincidofovir programs" after the oral nucleotide analog's top-line phase III failure in the trial called SUPPRESS, which tested the compound against cytomegalovirus in hematopoietic cell transplant patients. Read More

Damage from power outage at USPTO adds to patent uncertainty

While several patent questions continue to hang over the life sciences sector as 2015 gives way to the new year, the most immediate one concerns the lingering impact from last week's disabling power disruption at the U.S. Patent and Trademark Office's (USPTO) headquarters in Alexandria, Va. Read More

Gene editing, repair are among 2015's top science news

In a way, it was a back to the base-ics year for scientific advances. Two of the biggest science stories of the year are about the fundamental building block of biotechnology, namely, DNA – how to repair it in one case and how to edit it in another. Read More

Recursion's automated image analysis: New uses for old compounds

DUBLIN – Will tempol, a tool compound long used for its intracellular antioxidant effects, prove to be of clinical benefit to patients with cerebral cavernous malformation (CCM)? Read More

New Zealand is quietly building oncology immunotherapy expertise

As a small country, New Zealand has always needed to punch above its weight to be noticed, whether in sports, entertainment or science. With its rugby team the All Blacks recent winners of the Rugby World Cup, and the global success of the "Lord of the Rings" and "The Hobbit" film trilogies, there's another area where New Zealand is overachieving considering its population of just 4 million: cancer immunotherapy. Read More

Financings

Northwest Biotherapeutics Inc., of Bethesda, Md., said it the closed its previously announced registered direct placement with health care-focused institutional investors, for gross proceeds of $12.6 million. Read More

Other news to note

Epizyme Inc., of Cambridge, Mass., said the FDA's division of hematology products has accepted the company's investigational new drug application for tazemetostat for the treatment of adults with diffuse large B-cell lymphoma (DLBCL). Read More

Stock movers

Read More

In the clinic

Rich Pharmaceuticals Inc., of Beverly Hills, Calif., said the company has received FDA approval to begin its phase I/II trial for the treatment of acute myelocytic leukemia and myelodysplastic syndrome patients. Read More

Appointments and advancements

Therabron Therapeutics Inc., of Rockville, Md., named Thomas F. Miller president and CEO. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 27, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 27, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 24, 2025
  • BIO2025: John Crowley and Martin Makary

    BIO 2025: Makary lays out FDA’s path, launches pilot review program

    BioWorld
    On the same day that FDA Commissioner Martin Makary spoke in a fireside chat during the 2025 Biotechnology Innovation Organization’s International Convention, the...
  • Andembry

    New orphan drug, CSL’s garadacimab, cleared for hereditary angioedema

    BioWorld
    Following a complete response letter issued last October over CMC issues, CSL Behring LLC gained U.S. FDA approval June 16 of its humanized anti-factor XIIa...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe